0
0
NEW DELHI — In a move that signals a transition from pandemic-era recovery to long-term innovation, the Indian Government announced today that it will not grant an extension to the current Production Linked Incentive (PLI) scheme for Bulk Drugs. Despite pressure from manufacturing applicants, officials stated that maintaining the original timelines is essential to reward high-performing companies and safeguard the integrity of India’s pharmaceutical mission.
The decision, communicated by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply to the Lok Sabha on March 13, 2026, marks a pivotal moment for the “Pharmacy of the World.” As the original $830 million (₹6,940 crore) PLI scheme for Active Pharmaceutical Ingredients (APIs) matures, the government is pivoting its financial weight toward the high-tech frontier of biologics and biosimilars through the newly unveiled ₹10,000 crore Biopharma SHAKTI program.
Securing the Supply Chain: The API Success Story
For decades, India has faced a structural vulnerability: a heavy reliance on imported APIs—the raw “biologically active” components in drugs—particularly from single-source countries like China. When the COVID-19 pandemic shuttered global borders, this dependence threatened to halt the production of life-saving medicines.
The PLI Scheme for Bulk Drugs was the surgical response to this crisis. By December 2025, the impact of this domestic push became clear:
-
National Scale: 38 projects covering 28 notified products have been commissioned.
-
Capacity: India has established a domestic manufacturing capacity of approximately 56,800 metric tonnes (MT) per annum.
-
Regional Impact: In Maharashtra alone, an investment of ₹159 crore has yielded 17,680 MT of annual capacity, significantly buffering the state’s API base.
“The refusal to extend the scheme sends a clear message to the industry: efficiency and speed are non-negotiable,” says Dr. Arindam Sen, a pharmaceutical policy analyst not involved in the government report. “By sticking to the 2026 milestones, the government is filtering for ‘performers’ who can actually compete on a global stage without perpetual subsidies.”
The Pivot to “Biopharma SHAKTI” and Innovation
While the API scheme focused on traditional chemical synthesis, the future of medicine lies in Biologics—complex medicines derived from living organisms used to treat cancer, rheumatoid arthritis, and rare genetic disorders.
The Biopharma SHAKTI scheme, with its ₹10,000 crore outlay over five years, aims to transform India into a global hub for these complex therapies. Unlike simple pills, biologics require a sophisticated ecosystem of research, clinical trial infrastructure, and specialized manufacturing.
Accompanying this is the PRIP (Promotion of Research and Innovation in Pharma MedTech) scheme. With a ₹5,000 crore budget, PRIP is designed to move India from “volume” to “value.”
-
₹700 crore is dedicated to establishing Centers of Excellence (CoEs) at seven National Institutes of Pharmaceutical Education & Research (NIPERs).
-
₹4,200 crore is earmarked to stimulate private sector R&D.
Regional Research Clusters: A Top-Down Approach
To ensure self-reliance isn’t just a buzzword, the Department of Science and Technology (DST) has organized the country into five “Therapeutic Chemicals” clusters:
-
Chennai-Tirupati-Bengaluru
-
Hyderabad
-
Mumbai-Pune
-
Dehradun-Himachal
-
Kolkata-Guwahati
These clusters act as localized engines where academia and industry collaborate to identify priority chemicals and fast-track their commercialization.
What This Means for Public Health and the Consumer
For the average citizen, these high-level policy shifts have two direct consequences: Affordability and Availability.
-
Price Stability: By manufacturing 41 critical APIs domestically, India is less susceptible to international price spikes or supply chain “choke points” that can lead to medicine shortages in local pharmacies.
-
Advanced Treatments: The focus on Biosimilars (the generic versions of biologics) via Biopharma SHAKTI is expected to drastically lower the cost of expensive treatments like insulin and monoclonal antibodies for cancer.
However, the government is also balancing this with trade realities. Minister Patel noted that import duties on advanced medical equipment, such as cancer radiation technology, are under constant review. The goal is a “Goldilocks” tariff: low enough to ensure hospitals can afford life-saving tech, but high enough to encourage companies to eventually build that tech within India.
Challenges and Counter-Perspectives
While the government’s stance on “no extensions” promotes accountability, some industry experts worry about the smaller players.
“Manufacturing APIs is a capital-intensive, low-margin business with strict environmental regulations,” notes a representative from a regional pharmaceutical association. “While the leaders have crossed the finish line, smaller units struggling with post-pandemic inflation may find the lack of an extension a bitter pill to swallow.”
Furthermore, critics point out that while capacity has been established, the real test will be whether Indian-made APIs can remain price-competitive with imports once the incentive period ends.
The Road Ahead
As India sunsets the initial phase of its bulk drug incentives, the focus shifts to the laboratory. With the establishment of the NIPER Centers of Excellence and the massive injection of funds into the Biopharma SHAKTI scheme, the “Pharmacy of the World” is attempting to evolve into the “Laboratory of the World.”
For healthcare professionals, this suggests a future with more domestic options for complex therapies. For patients, it promises a more resilient healthcare system where the medicine on the shelf doesn’t depend on the stability of a single foreign port.
Reference Section
Official Sources:
-
Ministry of Chemicals and Fertilizers: “Extension of PLI Scheme to API,” Press Information Bureau (PIB) Delhi, March 13, 2026.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
